Patients with infl ammatory bowel disease (IBD) may be at increased risk for infections. We aimed to determine the pneumonia risk in IBD and how specifi c medications affect this risk.
INTRODUCTION
Patients with infl ammatory bowel disease (IBD), particularly those treated with immunosuppression, are at increased risk for infectious complications. In fact, infectious complications are among the most common causes of death in patients with IBD ( 1 ) . In the United States, community acquired pneumonia (CAP) is the leading infectious cause of death ( 2 ) . Th e most common etiologic agent of CAP in the United States is pneumococcal pneumonia. In 2004, there were an estimated 866,000 cases of pneumococcal pneumonia in the United States with estimated costs of 2.5 billion dollars ( 3 ) .
Little is known about the risk of pneumonia in IBD patients. In a recent study of death certifi cates, respiratory illness was identifi ed as a common cause of mortality in IBD patients ( 1 ) and bacterial pneumonia has been one of the most frequently reported complications in IBD clinical studies ( 4 ) . In the rheumatoid arthritis (RA) population, pneumonia has been shown to be a major cause of morbidity and mortality ( 5, 6 ) . In these patients, prednisone use has been associated with an increased risk of pneumonia hospitalization ( 5 ) . Th e anti-tumor necrosis factor-alpha (anti-TNF) agents have been associated with an increased overall risk of infection in
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Increased Risk of Pneumonia Among Patients With IBD some ( 7, 8 ) , but not in all ( 9 ) studies. Anti-TNF agents have not been found to increase the risk of hospitalization for pneumonia in RA ( 5 ) . Understanding medication-specifi c risks of pneumonia in IBD is important, as vaccination is available against the most common etiologic agent of pneumonia, Streptococcus pneumonia. Unfortunately, pneumococcal vaccination is currently underutilized in IBD populations ( 10 ) . Medication-specifi c pneumonia risk estimates in the IBD population may infl uence vaccination rates.
To further evaluate pneumonia risk in the IBD population, we aimed to determine this risk in patients with IBD as compared with a non-IBD cohort. We also aimed to determine whether specifi c immunosuppressive medications, narcotics, or protonpump inhibitors (PPIs) increase the risk of pneumonia in patients with IBD.
METHODS
We analyzed the procedural and outpatient pharmaceutical insurance claims contained in the LifeLink Health Plan Claims Database, Inc. (a unit of IMS, Watertown, MA, Copyright 2009, All Rights Reserved), for the period of January 1997 through 31 December 2009. Th is longitudinal, patient-level database has been used in previous epidemiologic studies of IBD ( 11, 12 ) . At the time of the extraction, the source database contained enrollment information on over 60 million persons from over 98 health plans across the United States. Th e included health-care plans capture a geographically diverse sample from across the United States. Only health plans that submitted data for all members were included in the database, ensuring complete data capture and representative samples. Prior studies have reported the IMS Health database to be representative of the national commercially insured population on a variety of demographic measures, including geographic region, age, gender, and health plan type ( 13 ) .
Study design
We performed a retrospective cohort study to determine the overall risk of pneumonia in IBD patients compared with a non-IBD cohort and a nested case -control study to determine the independent eff ects of medication use (immunosuppressive, biologic anti-TNF therapy, narcotics and corticosteroids) on pneumonia risk among patients with IBD. A similar design has previously been used by our group ( 11 ) and also by Gupta et al. ( 14 ) to evaluate the incidence of disorders in patients with IBD and the eff ects of various medications.
Cohort study
Patient selection . All patients aged < 64 years with at least 12 months of continuous health plan enrollment were eligible for inclusion in this analysis. We chose 64 as the upper age limit to avoid the possibility of missing data resulting from Medicare dual eligibility (which begins at age 65 years). Individuals were also required to have ongoing pharmacy coverage with their health plan to fully capture medication exposures. Th is was defi ned as no lapse of >1 month in pharmacy coverage during their inclusion in the cohort. We identifi ed cases of Crohn ' s disease (CD) and ulcerative colitis (UC) using a previously reported administrative defi nition expanded to include updated medications recently approved for IBD indications ( 15 ) . Th e precise defi nition included patients with at least three health-care contacts, on diff erent days, associated with an International Classifi cation of Diseases, 9th Revision, Clinical Modifi cation (ICD-9) diagnosis code for CD (555.xx) or UC (556.xx), or patients with at least 1 claim for CD or UC and at least 1 pharmacy claim for any of the following medications: mesalamine, olsalazine, balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine, methotrexate, infl iximab, adalimumab, certolizumab pegol, natalizumab, and enteral budesonide. For patients who had claims for both CD and UC, disease assignment was made according to the majority of the last nine claims or the majority of total claims if there were fewer than nine. If there were equal numbers of claims for CD and UC, then the individuals were classifi ed as IBD unspecifi ed. We matched each IBD patient to four non-IBD subjects by age, gender, calendar time, and US census region. Region of the country was defi ned by standard regional defi nitions from the US Census Bureau. We ensured that each non-IBD subject was enrolled during the same calendar time as the IBD subject to account for the seasonality of pneumonia outcomes. All individuals with any ICD-9 code for HIV (042-044.9) were excluded related to diff erences in susceptibility to infections.
Cohort lead time and follow-up . Each cohort member was required to have a minimum of 6 months of health plan enrollment before cohort entry. Th is " screening period " was used to assess potential confounders of interest. Entry into the IBD cohort began at the fi rst IBD claim determining their exposure status (regardless of the duration required to meet the IBD defi nition) and entry into the non-IBD cohort occurred in matched fashion based on calendar time. Each member of cohort was followed until the fi rst diagnosis of pneumonia, or, if none, until censoring at the earlier of one of two events: discontinuation of primary or pharmacy insurance coverage, or age >64.
Assessment of outcome (pneumonia)
. Pneumonia was defi ned as (i) any one ICD-9 code for bacterial pneumonia (481, 482.xx-483. xx, 485, 486) combined with a prescription for a systemic antibiotic or (ii) any hospital confi nement code accompanied by one of the above ICD-9 codes for bacterial pneumonia. Codes for viral or fungal pneumonia were not included in either defi nition. For the fi rst defi nition, the antibiotic prescription had to be fi lled in the time period of 1 week before 1 week aft er the pneumonia ICD-9 code. Antibiotic prescriptions for any of the following classes (any day supply) were included in the defi nition: macrolide class (erythromycin, clarithromycin, and azithromycin), penicillin class (amoxicillin, ampicillin, oxacillin, penicillin, dicloxacillin, nafcillin, oxacillin, amoxicillin / clavulanate), third-or fourth-generation fl uoroquinolone class (levofl oxacin, moxifl oxacin, gatifl oxacin, and gemifl oxacin), third-or fourth-generation cephalosporin class (cefdinir, cefi xime, cefotaxime, cefpodoxime, ceft ibuten, ceft izoxime, ceft riaxone, cefoperazone, ceft azidime, and cefepime), or tetracycline class (tetracycline, minocycline, and doxycycline).
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Of note, ciprofl oxacin (a second-generation fl uoroquinolone) was not included as part of the pneumonia outcome, as this antibiotic is not a " respiratory fl uoroquinolone " ( 16 ) and is oft en used for an indication of IBD independent of infection. A similar defi nition for outpatient pneumonia consisting of medication dispensing and ICD-9 codes has been used in prior studies of CAP using administrative data ( 17 ) . We also investigated a more sensitive secondary defi nition of pneumonia consisting only of any one of the above ICD-9 codes for bacterial pneumonia. Finally, a defi nition including all of the above factors (ICD-9 and antibiotic) and a chest X-ray was investigated. To ensure that the 12,407 outcomes of pneumonia observed in the cohort were incident rather than prevalent outcomes, we looked at the 30-day claim history before cohort entry and found zero claims for pneumonia during this period.
Assessment of exposures . All exposure assessment occurred during the 6-month " screening period " before cohort entry. Healthcare utilization was estimated in a continuous manner by the total of days with at least one health-care contact over the time period. Utilization has been measured in this manner in prior pharmacoepidemiology studies ( 18 ) . Comorbidities were assessed using the Quan update ( 19 ) of the validated Deyo comorbidity index for administrative data ( 20 ) . Medications, including systemic corticosteroids, immunomodulators, biologics, and 5-aminosalicylic acid (5-ASA) agents, were assessed in the exposure period in an any / none manner. Additionally, as PPI use can be associated with IBD and also with pneumonia, any PPI use was also extracted during the exposure period.
Evaluation of an alternate cohort . To cross-validate the outcome of pneumonia within our data set, we also investigated the risk of pneumonia in a separate cohort of individuals with diabetes mellitus as compared with a non-diabetic cohort, using the same methodology as that used in the IBD cohort. Diabetes was chosen as a reference population due to the known increased risk of pneumonia ( 21 ) and death from pneumonia in this population ( 22 ) . Diabetes was defi ned using any two separate ICD-9 codes for diabetes (250 -250.7).
Statistical analysis . We used descriptive statistics to summarize the characteristics of patients with and without IBD. Continuous variables are reported as mean ± standard deviation or median and interquartile range (IQR), and categorical variables are reported as percentages. We then calculated incidence rates of pneumonia (per 10,000 person-years) and used incidence rate ratios (IRRs) and 95 % confi dence intervals (CIs) to compare the incidence of pneumonia in IBD and non-IBD patients. We also performed subsequent analyses, stratifying by age (in decades), disease type (UC vs. CD), and comorbidity status. We assessed for possible violation of the proportional hazards assumption via log-log plots. As the assumption was not violated, we used Cox proportional hazards models to calculate hazard ratios (HRs) and 95 % CIs for the risk of pneumonia in the IBD cohort as compared with the non-IBD cohort, controlling for health-care utilization and comorbidities. Analyses were repeated stratifi ed by CD vs. UC, comorbidity status, and within the alternate diabetes cohort.
Nested case -control study
We next conducted a case -control study evaluating the association between corticosteroids, immunosuppressive or biologic anti-TNF medication use, narcotics and pneumonia. Th is study was nested within the previously defi ned cohort of patients with IBD.
Selection of cases and controls . Cases were those IBD patients who were diagnosed with pneumonia, and controls were those IBD patients without pneumonia. Each case patient was matched on gender, age, geographic region, disease type (CD or UC), and duration of follow-up to four IBD patients who did not have pneumonia using incidence density sampling. In this sampling technique, a case patient can also be a control patient provided that the case patient has not yet been diagnosed with pneumonia (has not yet become a case) at the time he or she is selected as a control. Once a case is diagnosed with pneumonia, he or she is no longer eligible to become a control or a case again. A total of 756 patients were included as both cases and controls. Each control was assigned an index date identical to the matched case ' s date of pneumonia, to account for seasonality.
Assessment of outcome (pneumonia)
. Th e outcome was outpatient or inpatient pneumonia, as defi ned within the cohort study by ICD-9 codes, antibiotic prescriptions, and hospital confi nement codes.
Assessment of exposures . Medication use
. Th e primary medications evaluated included azathioprine and 6-mercaptopurine (thiopurine class), methotrexate, tacrolimus, and cyclosporine (calcineurin class), mycophenolate mofetil, infl iximab, adalimumab, and certolizumab pegol (biologic anti-TNF class), and systemic corticosteroids. PPI use was also assessed, as this could be associated with both exposure and outcome. Any narcotic use was assessed as well. Medication exposures were analyzed with respect to the amount of time preceding the diagnosis of pneumonia in cases or the corresponding index date in controls. All exposures were defi ned as at least one outpatient pharmacy claim occurring during the 120 days before pneumonia diagnosis.
Potential confounders . Data on utilization and comorbidities were also included as exposure variables in the case -control study. Th ese variables were assessed during the 6-month exposure period before pneumonia diagnosis. Utilization was defi ned in a continuous manner as total number of days with at least one health-care contact. Comorbidities were assessed through the Quan update ( 19 ) of the validated Deyo comorbidity index ( 20 ) for administrative claims data.
Statistical analysis . Characteristics of cases and controls were described using descriptive statistics. We then used conditional logistic regression to calculate odds ratios (ORs) and 95 % CIs for each medication exposure related to the outcome of pneumonia.
We constructed a full model by using all potential confounders
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and eliminated these confounders via a backwards elimination strategy by using a change in estimate approach (threshold of < 10 % change). Analyses were performed for patients with IBD and also stratifi ed by UC and CD diagnosis.
For all analyses, P values were two-sided, and a P value of 0.05 or less was considered as statistically signifi cant. All statistical analyses were performed using Stata version 11.0 (College Station, TX). Th e study protocol was granted exemption from review by the Institutional Review Board at University of North Carolina because it involved the use of existing, de-identifi ed data.
RESULTS
Th e cohort study population included 108,604 patients with IBD. Of these, 50,932 had CD, 56,403 had UC, and 1,269 had IBD with unknown type. Th ere were a total of 434,416 individuals in the non-IBD comparison cohort. Th e median length of follow-up within this cohort was 24 months (IQR 12 -42) with a range from 1 to 138 months aft er the 6-month " screening " period. Length of follow-up was similar for CD (34 months, IQR 19 -51) and UC populations (36 months, IQR 21 -54), while signifi cantly less in the non-IBD comparison cohort (21 months, IQR 10 -38). with an IRR of 1.85, 95 % CI 1.79 -1.90 for pneumonia risk in the IBD cohort as compared with the non-IBD cohort.
In the alternate diabetes cohort, the risk of recorded pneumonia in diabetics as compared with non-diabetics was elevated to a similar extent (IRR 2.26, 95 % CI 2.17 -2.35). Th e overall incidence of pneumonia among diabetics was 178 / 10,000 as compared with 79 / 10,000 in the non-diabetic cohort. In adjusted analyses, adjusting for health-care utilization and comorbidities, the risk estimate remained similar (HR 1.84, 95 % CI 1.76 -1.93).
In the nested case -control study, 4,856 IBD patients with pneumonia were matched to 18,928 IBD patients without pneumonia. Th e characteristics of the populations are shown in Table 3 for specifi c medication use in the overall population, and by IBD subtype.
DISCUSSION
In this large cohort of commercially insured Americans, we have demonstrated an increased risk of recorded pneumonia in patients with IBD as compared with the general population, with an adjusted eff ect estimate of HR 1.54, 95 % CI 1.49 -1.60. Interestingly, when we looked only at hospitalized pneumonia, the eff ect estimate was further increased for IBD as compared with non-IBD. Th is may be related to more severe infection in IBD patients, to a lower threshold for hospitalization, or possibly related to pneumonia acquired during a hospitalization for another indication (such as IBD). Additionally, we found a particularly increased risk of recorded pneumonia among patients on corticosteroids (OR 1.91, 95 % CI 1.72 -2.12) or narcotics (OR 2.28, 95 % CI 2.09 -2.48), a mild-to-moderate increased risk in patients on biologic anti-TNF agents (OR 1.32, 95 % CI 1.11 -1.57), a mild risk with thiopurines (OR 1.13, 95 % CI 1.00 -1.27) and no increased risk associated with 5-ASA medications. To our knowledge, this is the fi rst epidemiological study of the incidence and medication-specifi c risk factors for pneumonia in patients with IBD. Interestingly, these fi ndings are consistent with emerging studies in the RA literature suggesting a moderately strong risk of pneumonia attributable to corticosteroids ( 5,6 ), a possible increased risk of hospital infection attributable to anti-TNF agents ( 8, 9 ) , and no risk associated with other disease modifying antirheumatic drugs (DMARDs ) such as methotrexate ( 8 ) .
Th ese fi ndings are particularly important given that vaccination against invasive Streptococcus pneumonia , the most common cause of CAP, is available in the United States for both children and adults and is recommended in IBD immunization Characteristics of the patients with IBD as compared with the non-IBD cohort are shown in Table 1 . Th ere was increased healthcare utilization, immunosuppressive medication use, and PPI use among the IBD cohort as compared with the matched non-IBD cohort, as expected. Th ese same factors were increased in those with CD as compared to those with UC. Among the IBD cohort, there were also slightly higher rates of liver disease and chronic obstructive pulmonary disease (COPD) as compared with the non-IBD cohort.
For patients with IBD, the overall annual incidence of recorded pneumonia was 138 / 10,000, compared with 76 / 10,000 in the non-IBD cohort (IRR 1.82, 95 % CI 1.75 -1.88) ( Figure 1 ). Th e risk was somewhat greater for CD as compared with non-IBD (IRR 2.05, 95 % CI 1.94 -2.15) than for UC as compared with non-IBD (IRR 1.62, 95 % CI 1.54 -1.71). We also stratifi ed these analyses by comorbidities. In general, the incidence of pneumonia was higher in individuals (both IBD and non-IBD) with comorbidities than without comorbidities. Th e RRs of pneumonia in IBD patients, vs. non-IBD patients, are attenuated in individuals with each comorbidity, as compared to individuals without comorbidity ( Supplementary Table 1 ). Th e incidence of recorded pneumonia was then evaluated in strata of age, with the highest incidence in the 60 + age strata (226 / 10,000). In a subanalysis, adding the requirement of chest X-ray to the outpatient pneumonia diagnosis, the overall IRR for pneumonia did not change (IRR 1.71, 95 % CI 1.63 -1.79 for IBD vs. non-IBD). Finally, an additional subanalysis investigating the outcome of only hospitalized pneumonia demonstrated that the relative risk (RR) was further increased among the IBD population (IRR 2.70, 95 % CI 2.49 -2.94 for IBD vs. non-IBD).
On adjusted Cox analysis, controlling for comorbidities, healthcare utilization, and PPI use, the RR of recorded pneumonia remained elevated in the overall IBD population (HR 1.54, 95 % CI 1.49 -1.60). Compared with the matched non-IBD cohort, the risk was greater for CD (HR 1.71, 95 % CI 1.62 -1.80) than for UC (HR 1.41, 95 % CI 1.34 -1.48). Analyses were also performed using the alternate defi nition of pneumonia (any one ICD-9 code). Th e eff ect size estimate remained similar with this alternate defi nition, guidelines ( 23 ) . As hospitalization for pneumonia has been associated with excess mortality in the IBD population (OR 3.6, 95 % CI 2.9 -4.5) ( 24 ), understanding medication-specifi c risk factors for pneumonia becomes important. We also investigated the age-specifi c risks of pneumonia in patients with IBD, and found the highest RRs in the younger ( ≤ 30 years) group, with the highest absolute risk in the elderly (61 -64). Th is is not dissimilar to the general population and the previously described studies of RA ( 5, 6 ) , where elderly individuals are at the highest absolute risk for pneumonia. In the IBD population, the greatest absolute diff erences in mortality rates for IBD as compared with the general population occur in the elderly ( 25 ) , as do diff erences in mortality risks for pneumonia ( 24 ) . As in the general population, we also found that comorbidities, including COPD, were additional risk factors for pneumonia in the IBD population.
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Our study has also confi rmed two known associations, which help to substantiate the validity of our novel IBD-related fi ndings. First, the RR of pneumonia in IBD, particularly for those with CD (HR 1.71, 95 % CI 1.62 -1.80), was on par with the RR in a separate diabetes population (HR 1.84, 95 % CI 1.76 -1.93). Other studies have found diabetes to be associated with an increased risk of pneumonia (HR 1.92, 95 % CI 1.84 -1.99) ( 21 ) and death from pneumonia (HR 1.67, 95 % CI 1.45 -1.92) ( 22 ) . Additionally, recent data show an increased risk of pneumonia associated with PPI use. Th e mechanism behind this increased risk is hypothesized to be overgrowth of bacteria due to acid suppression in the stomach, which may increase the risk of micro-aspiration of bacteria, and therefore pneumonia ( 26 ) . We found an increased risk of pneumonia associated with PPI use in our IBD population (unadjusted OR 2.21, 95 % CI 2.04 -2.39, adjusted OR 1.15, 95 % CI 1.04 -1.26). Such fi ndings are consistent with the mild increased risk found in a recently published meta-analysis of PPI use and pneumonia (OR 1.36, 95 % CI 1.12 -1.65) ( 26 ) . Additionally, we found an increased risk of pneumonia in those with recent narcotic use. Animal studies have demonstrated an immunosuppressive eff ect of opioid dependency, due to the eff ects of opioids on innate and adaptive immunity ( 27 ) . Similar to our fi ndings, in studies of the older adult general population, opioids are associated with an increased pneumonia risk ( 28 ) . Narcotic use in IBD populations has been previously associated with increased serious infection risk, supporting our fi ndings ( 29 ) . Importantly, many of these classes of medications are also associated with more severe IBD. Th erefore, the associations we found could also be a factor of the immune dysfunction associated with severe IBD.
Th ere are notable strengths to this study of pneumonia in IBD. First, we studied a large and geographically diverse population. By drawing from a large number of health plans of varying size, type, and location, we believe these results to be broadly generalizable to the commercially insured US population. Second, we utilized complete data on all billed outpatient prescriptions to completely capture medication exposures; rather than relying on patient recall. Th ird, we were also able to account for health-care utilization, other pharmacologic exposures such as PPIs and narcotics, that have been associated with pneumonia, and multiple comorbidities,
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Additionally, although we controlled for health-care utilization, comorbidities, and PPI use, we were unable to other potential confounders such as smoking status. However, we were able to control for COPD, which has been used as a proxy for smoking status in other studies using administrative data. Additionally, we did a separate analysis evaluating the role of smoking as an unmeasured confounder using the method of Schneeweiss ( 32 ) . In this analysis, we found that in order for the diff erence we found in pneumonia risk in the cohort (IRR 1.8) to be entirely related to smoking as a confounder; smoking would need to increase the risk of pneumonia by sixfold, and those with IBD would need a fi vefold increase in smoking as compared with the general population. In fact, smoking is known to increase the risk of pneumonia by only twofold ( 33 ) and smoking prevalence in IBD is not fi ve times greater than the general population (smoking estimate in general population is 20 % among young adults) ( 34 ) . Th erefore, smoking as an unmeasured confounder does not fully explain our association. We repeated a similar analysis for our nested case -control study and found that smoking as an unmeasured confounder could not fully account for the diff erence in pneumonia risk we found among biologic users. Another limitation is that we were also unable to account for over the counter PPI use, which has been available since 2003. Due to our study design, where individuals with IBD contributed time from their fi rst claim for IBD, there is the potential for immortal time bias, therefore underestimating the true risk relationship between IBD and pneumonia ( 35 ) . As IBD is a chronic disorder in which symptoms can be ongoing for some time before diagnosis, we felt that this design was most appropriate. Nonetheless, we calculated the proportion of immortal time in our cohort using the method published by Suissa ( 35 ) and found it below the threshold needed to introduce bias. Despite these limitations, several factors speak to the internal validity of the fi ndings reported here including (i) consistency of our fi ndings with other known risk factors for pneumonia (diabetes ( 21 ) , PPI use ( 26 ), many of which are associated with pneumonia, using a validated comorbidity index ( 19, 20 ) .
Th ere are also several limitations to this study of administrative claims data. Th ere is the possibility of misclassifi cation of exposure and outcome related to the lack of clinical detail. We did use an IBD exposure defi nition previously used by our group ( 11, 12 ) that requires multiple health contacts and / or IBD-related prescriptions. A similar, but even less specifi c, administrative case defi nition has been validated by Herrinton et al. 30 Th e Herrinton defi nition was found to have a sensitivity exceeding 90 % and a PPV exceeding 80 % for overall IBD ( 30 ) . We used an outcome defi nition of pneumonia that required both an ICD-9 code for pneumonia and a separate code for an antibiotic dispensing and / or hospitalization, as prior validation studies of pneumonia indicated that ICD-9 codes alone were imprecise ( 31 ) . A similar defi nition of ICD-9 codes with antibiotic dispensing has been used in prior studies of pneumonia ( 17 ) . However, this defi nition has not been validated. We also performed several sensitivity analyses around the outcome defi nition by investigating a more sensitive defi nition consisting of any one ICD-9 code and a more specifi c defi nition requiring a chest X-ray in addition to the above criteria, and the eff ect estimate for pneumonia risk did not change. Another limitation is that we could not determine whether pneumonia diagnoses were community or hospital acquired. However, we have identifi ed individuals with a prior hospitalization within 30 days of pneumonia diagnosis as " possible hospital acquired pneumonia " . A total of 546 of the 12,407 cases of pneumonia in the cohort had a prior hospitalization (346 with IBD and 200 without IBD). When we excluded these individuals, the IRR for IBD as compared with non-IBD did not change (1.7 vs. 1.8, with overlapping CIs). It is also possible that IBD patients, due to increased utilization, will have increased recording of comorbidities when compared with the non-IBD cohort. To assess for this, we performed analyses stratifi ed by each comorbidity, and the risk estimates were not aff ected. increasing age) and (ii) a fi nding of no association between pneumonia and 5-ASA use, which can be considered as a negative control. A fi nal limitation to this study is that the elderly (>age 65) and uninsured were not represented in our population. Th e lack of older persons in our study population does not aff ect the validity of the RRs (IRRs, HRs, and ORs) we presented in the context of the under 65 population.
In conclusion, we believe that the associations between specifi c medication classes and increased risk of pneumonia in patients with IBD should be viewed as a call to action; particularly in regards to corticosteroid use. As both corticosteroid use ( 36 ) and pneumonia ( 24 ) have been associated with excess mortality risk in patients with IBD, implications for prevention are of great consequence. We also found an association between narcotic use and pneumonia in IBD. Avoiding narcotics and emphasizing other forms of pain control are therefore of even greater importance. Pneumococcal vaccination is safe, eff ective, widely available, and known to prevent complications of pneumococcal pneumonia. Unfortunately, current vaccination eff orts in the IBD population are lagging. In one tertiary care setting, only 9 % of patients with IBD reported pneumococcal vaccination ( 10 ) . As response to vaccination can be impaired with immunosuppression ( 37 ), the optimal time to vaccinate individuals with IBD is likely at diagnosis. Knowing risk factors for pneumonia in the IBD population, such as age and comorbidities, may increase awareness and promote prevention and / or early treatment. Additionally, awareness of the medication-specifi c associations: corticosteroids, anti-TNF agents, thiopurines, PPIs, and narcotics may provide for timely intervention and ultimately improve outcomes.
